

# EastGate Acquisitions Augments Its Sub-Micron Self- Nanoemulsifying Platform Technology

✘ August 18, 2014 (Source: PR Newswire) – EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it is augmenting its self-emulsifying sub-micron platform technology to include a broad spectrum of delivery options. The various technologies are applicable to the company's current pharmaceutical products in development and can also be employed as effective platforms for delivery of other biologically active compounds. The company recently expanded its new product development to include large molecules as active compounds that will address indications in diabetes, obesity and the overall metabolic syndrome.

The company's technology platform led to the development of several improved novel formulations and alternative dosage forms for delivery of known biologically active molecules. The technology utilizes EastGate's sub-micron self-emulsifying delivery vehicle and facilitates the creation of harmonized formulations with better drug absorption. The company's technological approaches have demonstrated robustness and resulted in diversification of the drug delivery products. The variety of developed dosage forms includes liquid spray or droplets, semi-solid, compressed tablets and capsules of different types.

The purpose of offering this spectrum of dosage forms is to provide patients with different treatment possibilities and

bring products that will fit their lifestyle and improve patient's compliance.

Currently the company is working towards acquiring the licensing rights to develop and manufacture an intraoral insulin formulation. The intraoral insulin dosage forms under consideration are liquid and solid dosage forms, such as compressed tablet which can be delivered to the mouth for intraoral absorption.

"We have recognized the importance of expanding our sub-micron self-nanoemulsifying platform technology to include different dosage forms and delivery methods," says Anna Gluskin, EastGate's CEO. "The versatility of the sub-micron platform technology will continue to validate the company's sub-micron approach and provide a unique opportunity to offer different absorption-enhanced products to widen the target patient population," states Gluskin.

### **About EastGate Acquisitions Corporation**

EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada, is a pharmaceutical company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules. The Company's model is based on a two-tier business approach that includes development of novel pharmaceutical products and innovative dietary supplements. Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules. The Company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement,

enhanced vitamin delivery and skin conditions. EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development. We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate's approach will be most beneficial for patient care. For more information, please visit the company's website at [www.EastGatePharmaceuticals.com](http://www.EastGatePharmaceuticals.com).

### **Cautionary statement on forward-looking information**

*All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.*

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission,

*which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.*

**CONTACT:** Rose Perri 1-647-692-0652

**Email:** [information@eastgatepharmaceuticals.com](mailto:information@eastgatepharmaceuticals.com)

**Text:** ESAQ to 87804